Medical Affairs Department, Torii Pharmaceutical Co., Ltd., 3-4-1 Nihonbashi-Honcho, Chuo-Ku, Tokyo, 103-8439, Japan.
Aiiku Maternal and Child Health Center, Aiiku Hospital, 1-16-10 Shibaura, Minato-Ku, Tokyo, 105-8321, Japan.
BMC Womens Health. 2024 May 21;24(1):303. doi: 10.1186/s12905-024-03104-0.
Patients with iron deficiency anemia are treated with iron preparations, but gastrointestinal symptoms such as nausea and vomiting occur frequently. These symptoms may negatively affect the quality of life and work productivity in patients with iron deficiency anemia. This study assessed the impact of nausea and vomiting on the quality of life and work productivity of patients taking iron preparations for heavy menstrual bleeding or anemia.
An online survey was conducted among patients taking iron preparations for heavy menstrual bleeding or anemia. Demographic data and information about medication use and the health condition were collected. The patients were asked to answer the 5-level EQ-5D version, and work productivity and activity impairment questionnaires. The outcomes were reported by patients in the presences of nausea, vomiting, and nausea or vomiting. The association with the 5-level EQ-5D version utility score for the severity and frequency of the symptoms were also assessed.
A total of 385 patients were enrolled, and 96 were patients with nausea or vomiting, of which 94 were with nausea and 27 were with vomiting. The 5-level EQ-5D version utility scores for the patients with nausea, vomiting, and nausea or vomiting were significantly lower than those of the patients without these symptoms (p < 0.001 for each). The 5-level EQ-5D version utility score was correlated with the severity of nausea and the frequency of vomiting per day (p < 0.001 for each). As for the work productivity and activity impairment, the presenteeism, the overall work impairment, and the activity impairment of the patients with nausea, vomiting, and nausea or vomiting were significantly higher than those without these symptoms (p < 0.001 for each). The absenteeism was slightly higher trend was observed, but not significant.
Patients taking iron preparations who have nausea or vomiting experience a significant burden in terms of poorer quality of life and higher work productivity impairment.
UMIN000045700 ( http://www.umin.ac.jp/ctr/ ). Registered on October 11, 2021.
缺铁性贫血患者接受铁剂治疗，但常出现恶心和呕吐等胃肠道症状。这些症状可能会对缺铁性贫血患者的生活质量和工作生产力产生负面影响。本研究评估了恶心和呕吐对接受铁剂治疗月经过多或贫血的患者生活质量和工作生产力的影响。
对接受铁剂治疗月经过多或贫血的患者进行了在线调查。收集了人口统计学数据以及药物使用和健康状况信息。患者被要求回答 EQ-5D 5 级版本和工作生产力和活动障碍问卷。患者在存在恶心、呕吐和恶心或呕吐的情况下报告结果。还评估了与症状严重程度和频率相关的 EQ-5D 5 级版本效用评分的关联。
共纳入 385 例患者，96 例患者出现恶心或呕吐，其中 94 例出现恶心，27 例出现呕吐。出现恶心、呕吐和恶心或呕吐的患者的 EQ-5D 5 级版本效用评分明显低于无这些症状的患者（p 值均<0.001）。EQ-5D 5 级版本效用评分与恶心严重程度和每天呕吐频率相关（p 值均<0.001）。至于工作生产力和活动障碍，出现恶心、呕吐和恶心或呕吐的患者的出勤、总体工作障碍和活动障碍明显高于无这些症状的患者（p 值均<0.001）。旷工略高，但无统计学意义。
服用铁剂出现恶心或呕吐的患者生活质量较差，工作生产力受损程度更高。
UMIN000045700（http://www.umin.ac.jp/ctr/）。于 2021 年 10 月 11 日注册。
